1. Home
  2. DHC vs PHVS Comparison

DHC vs PHVS Comparison

Compare DHC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diversified Healthcare Trust of Beneficial Interest

DHC

Diversified Healthcare Trust of Beneficial Interest

HOLD

Current Price

$8.76

Market Cap

2.3B

Sector

Real Estate

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.99

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DHC
PHVS
Founded
1998
2015
Country
United States
Switzerland
Employees
585
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.4B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
DHC
PHVS
Price
$8.76
$34.99
Analyst Decision
Strong Buy
Buy
Analyst Count
3
11
Target Price
$8.00
$41.82
AVG Volume (30 Days)
1.8M
544.3K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
0.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.13
N/A
Revenue Next Year
$7.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$19.12
52 Week High
$9.66
$36.60

Technical Indicators

Market Signals
Indicator
DHC
PHVS
Relative Strength Index (RSI) 45.89 62.03
Support Level $8.19 $24.73
Resistance Level $9.14 N/A
Average True Range (ATR) 0.33 1.65
MACD -0.07 0.10
Stochastic Oscillator 12.13 67.66

Price Performance

Historical Comparison
DHC
PHVS

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: